Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Anavex Life Sciences (AVXL) stocks in Canada

Learn how to easily invest in Anavex Life Sciences stocks.

Anavex Life Sciences is a biotechnology business based in the US. Anavex Life Sciences stocks (AVXL.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $25.75 – a decrease of 2.85% over the previous week. Anavex Life Sciences employs 25 staff and has a market cap (total outstanding stock value) of $941.1 million.

How to buy shares in Anavex Life Sciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AVXL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Anavex Life Sciences stock price (NASDAQ:AVXL)

Use our graph to track the performance of AVXL stocks over time.

Anavex Life Sciences shares at a glance

Information last updated 2022-01-23.
Latest market close$12.29
52-week range$5.85 - $31.50
50-day moving average $17.92
200-day moving average $17.76
Wall St. target price$38.29
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.54

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Anavex Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Anavex Life Sciences price performance over time

Historical closes compared with the close of $12.29 from 2022-01-26

1 week (2022-01-21) -0.73%
1 month (2021-12-27) -35.65%
3 months (2021-10-28) -32.14%
6 months (2021-07-28) -42.46%
1 year (2021-01-28) 93.85%
2 years (2020-01-28) 312.42%
3 years (2019-01-28) 571.58%
5 years (2017-01-27) 191.23%

Anavex Life Sciences financials

Gross profit TTM $0
Return on assets TTM -23.87%
Return on equity TTM -42.58%
Profit margin 0%
Book value $1.99
Market capitalisation $941.1 million

TTM: trailing 12 months

Anavex Life Sciences share dividends

We're not expecting Anavex Life Sciences to pay a dividend over the next 12 months.

Have Anavex Life Sciences's shares ever split?

Anavex Life Sciences's shares were split on a 1:4 basis on 7 October 2015. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anavex Life Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Anavex Life Sciences shares which in turn could have impacted Anavex Life Sciences's share price.

Anavex Life Sciences share price volatility

Over the last 12 months, Anavex Life Sciences's shares have ranged in value from as little as $5.85 up to $31.5. A popular way to gauge a stock's volatility is its "beta".

AVXL.US volatility(beta: 0.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anavex Life Sciences's is 0.5651. This would suggest that Anavex Life Sciences's shares are less volatile than average (for this exchange).

Anavex Life Sciences overview

Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. .

Stocks similar to Anavex Life Sciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site